| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03618823 Details | 2021-11-10 Interventional | 1/2 | 268 | Acetaminophen Ibuprofen Oxycodone Agnosia Adenotonsillect… Opioid Use Post-operative … | Early termination due to COVID-19 cases and cancelled surgeries. Early termination due to COVID-19 cases and cancelled surgeries. | |||
| NCT04414631 Details | 2021-11-09 Interventional | 2 | 80 | Complement C1 I… COVID-19 Communicable Di… Coronavirus Inf… Infections | Aim to enroll 120 patients deemed not sufficient to show a difference in the primary outcome
measure. Standard of care treatment recently changed in Switzerland adding further
heterogeneity to trial population when including future participants. - | |||
| NCT03927911 Details | 2021-11-09 Interventional | 4 | 65 | Bupivacaine Pain, Postopera… Postoperative P… | Due to protocol feasibility given the rapid evolution of medical practice for spinal procedure.
Data from approximately 65 FUSION study subjects will be analyzed with the intent to create
either a future study or registry for this patient population. - | |||
| NCT03379259 2018-000265-37 Details | 2021-11-09 Interventional | 1/2 | 39 | Tislelizumab Neoplasms Advanced Solid … | Study Was Terminated Early Phase 2A of the study was not initiated nor conducted since BGB-A333 as a monotherapy treatment beyond the completion of dose escalation in Phase 1A was not pursued. | |||
| NCT03184558 2016-003608-30 Details | 2021-11-09 Interventional | 2 | 29 | Pembrolizumab Breast Neoplasm… Inflammatory Br… Triple Negative… Inflammatory Br… Triple Negative… | Based on planned futility assessment None of the participants achieved CR or PR. As there were no responses, the study was terminated. It was planned to terminate the trial in favor of the null hypothesis of futility when 5 or fewer responses were observed in 28 participants. | |||
| NCT04422210 2019-004487-22 Details | 2021-11-08 Interventional | 1 | 2 | Atezolizumab Carboplatin Etoposide Venetoclax Lung Neoplasms Small Cell Lung… Small Cell Lung… | Decision to discontinue the study based on broader development and strategic prioritisation.
The Sponsor concludes there is no benefit-risk impact on the GO41864 study. The study was terminated by the Sponsor. Only 2 participants were enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality. | |||
| NCT04298918 2019-004200-35 Details | 2021-11-08 Interventional | 1/2 | 1 | Ado-Trastuzumab… Maytansine Trastuzumab Venetoclax Breast Neoplasm… Breast Cancer | Decision to discontinue the study based on broader development and strategic prioritisation.
The Sponsor concludes there is no benefit-risk impact on the CO41863 study. The study was terminated by the Sponsor. Only 1 participant was enrolled in this study. Based on the low enrolment number, no data is reported here in order to protect and maintain participant privacy/confidentiality. | |||
| NCT03705273 Details | 2021-11-08 Interventional | 4 | 40 | BB 1101 Dexamethasone Dexamethasone a… Asthma Croup | Dr. Arnold assisted in designing and initiating study for a pharmacology PhD candidate. The
candidate left the institution and study enrollment was terminated. - | |||
| NCT00210119 Details | 2021-11-08 Interventional | 2 | 19 | Imatinib Mesyla… Leukemia Leukemia, Myelo… Leukemia, Myelo… Myeloid Leukemi… | - - | |||
| NCT02212574 Details | 2021-11-05 Interventional | 1 | 6 | Cyclophosphamid… Lomustine Vincristine Medulloblastoma | Participant relapses led to abrupt stop of study. Two of the participants relapsed not long into the study and the Data and Safety Management Committee (DSMC) recommended early closure of the study. | |||
| NCT00270257 Details | 2021-11-05 Interventional | 3 | 1251 | Buprenorphine Buprenorphine, … Naloxone Acquired Immuno… Communicable Di… HIV Infections Infections Opioid-Related … | DSMB halted the study due to futility as a result of lower than anticipated HIV incidence rates - | |||
| NCT02160730 Details | 2021-11-04 Interventional | 2 | 4 | Roscovitine ACTH-Secreting … Pituitary ACTH … Cushings Diseas… | NIH grant ended. - | |||
| NCT00000961 Details | 2021-11-04 Interventional | 2 | - | Immune Sera Zidovudine Acquired Immuno… HIV Infections Infections | - - | |||
| NCT04434001 Details | 2021-11-03 Interventional | 2 | 40 | Thrombin Acute Lung Inju… Heart Defects, … Heart Diseases Lung Injury Transfusion Rea… Transfusion-Rel… Bleeding Cardiac Defect Congenital Hear… Fibrinogenopeni… Surgery--Compli… Transfusion-Ass… | The study encountered unexpected difficulties in enrolling patients due to requirements for the
Informed Consent. 60% of our patients comes from abroad with only one accompanying parent. The
rules of our EC require both parents to sign the consent. - | |||
| NCT03769688 Details | 2021-11-03 Interventional | 1 | 0 | Metronidazole Vaginal Disease… Vaginosis, Bact… Bacterial Vagin… | Replaced with different study at another site. - | |||
| NCT02571530 Details | 2021-11-03 Interventional | 1 | 2 | Trastuzumab Neoplasm Metast… | Low enrollment - | |||
| NCT02438995 Details | 2021-11-03 Interventional | 1 | 11 | Cetuximab Carcinoma Carcinoma, Squa… Squamous Cell C… Carcinoma, Squa… | Low enrollment - | |||
| NCT00000730 Details | 2021-11-03 Interventional | 3 | - | Leucovorin Levoleucovorin Methylprednisol… Pentamidine Sulfamethoxazol… Trimethoprim Trimethoprim, S… Trimetrexate Pneumonia Pneumonia, Pneu… HIV Infections Pneumonia, Pneu… | - - | |||
| NCT04794205 Details | 2021-11-02 Interventional | 1/2 | 0 | Caryophyllene Beta-Caryophyll… | Delayed project onset; PI determined pilot data could be collected at a later date. - | |||
| NCT03645603 2015-002114-80 Details | 2021-11-02 Interventional | 2 | [1 Refs] | 45 | Dexmedetomidine Substance Withd… Withdrawal Synd… | futility reasons - |